

Viola W Zhu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6851781/publications.pdf>

Version: 2024-02-01

57
papers

4,324
citations

172457

29
h-index

161849

54
g-index

58
all docs

58
docs citations

58
times ranked

4113
citing authors

#	ARTICLE	IF	CITATIONS
1	Acquired Resistance to KRAS ^{G12C} Inhibition in Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 2382-2393.	27.0	482
2	Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers. <i>New England Journal of Medicine</i> , 2020, 383, 825-835.	27.0	454
3	Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i> -Mutant NSCLC and Clinical Validation of Combined <i>EGFR</i> and <i>RET</i> Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion. <i>Cancer Discovery</i> , 2018, 8, 1529-1539.	9.4	342
4	Repotrectinib (TPX-0005) Is a Next-Generation <i>ROS1/TRK/ALK</i> Inhibitor That Potently Inhibits <i>ROS1/TRK/ALK</i> Solvent- Front Mutations. <i>Cancer Discovery</i> , 2018, 8, 1227-1236.	9.4	321
5	Impact of <i>EML4-ALK</i> Variant on Resistance Mechanisms and Clinical Outcomes in <i>ALK</i> -Positive Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1199-1206.	1.6	246
6	Pralsetinib for <i>RET</i> fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 959-969.	10.7	222
7	Pralsetinib for patients with advanced or metastatic <i>RET</i> -altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 491-501.	11.4	192
8	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial. <i>Cancer Discovery</i> , 2021, 11, 1688-1699.	9.4	154
9	The race to target <i>MET</i> exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. <i>Lung Cancer</i> , 2017, 103, 27-37.	2.0	136
10	Emergence of novel and dominant acquired <i>EGFR</i> solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one <i>EGFR</i> (L858R/T790M) NSCLC patient who progressed on osimertinib. <i>Lung Cancer</i> , 2017, 108, 228-231.	2.0	125
11	Beyond Osimertinib: The Development of Third-Generation <i>EGFR</i> Tyrosine Kinase Inhibitors For Advanced <i>EGFR+</i> NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 740-763.	1.1	115
12	Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an <i>NTRK</i> Gene Fusion. <i>JCO Precision Oncology</i> , 2018, 2018, 1-12.	3.0	112
13	Receptor Tyrosine Kinase Fusions and <i>BRAF</i> Kinase Fusions are Rare but Actionable Resistance Mechanisms to <i>EGFR</i> Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1312-1323.	1.1	103
14	Emergence of Preexisting <i>MET</i> Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with <i>MET</i> Exon 14 Skipping. <i>Journal of Thoracic Oncology</i> , 2017, 12, 137-140.	1.1	102
15	Impact of <i>MET</i> inhibitors on survival among patients with non-small cell lung cancer harboring <i>MET</i> exon 14 mutations: a retrospective analysis. <i>Lung Cancer</i> , 2019, 133, 96-102.	2.0	85
16	Efficacy of Aumolertinib (HS-10296) in Patients With Advanced <i>EGFR</i> T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 411-422.	1.1	70
17	<i>EGFR</i> exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. <i>Lung Cancer</i> , 2020, 145, 186-194.	2.0	68
18	Dual occurrence of <i>ALK</i> G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation <i>ALK</i> inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?. <i>Lung Cancer</i> , 2017, 106, 110-114.	2.0	64

#	ARTICLE	IF	CITATIONS
19	U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 4785-4794.	7.0	63
20	Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1530-1538.	1.1	62
21	Catalog of 5â€™™ Fusion Partners in ALK-positive NSCLC Circa 2020. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100015.	1.1	62
22	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusionâ€™™Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2899-2909.	7.0	62
23	Liquid Biopsy to Identify Actionable Genomic Alterations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 978-997.	3.8	54
24	Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020, 15, 258-265.	1.1	53
25	Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. <i>Lung Cancer</i> , 2021, 158, 126-136.	2.0	53
26	Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Trends in Cancer</i> , 2019, 5, 677-692.	7.4	43
27	An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitorâ€™™Refractory ALK-Positive or ROS1-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1484-1496.	1.1	43
28	Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1611-1623.	1.1	43
29	CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome. <i>Lung Cancer</i> , 2019, 130, 201-207.	2.0	35
30	Clinicopathologic Features and Response to Therapy of <i>NRG1</i> Fusionâ€™™Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. <i>Journal of Clinical Oncology</i> , 2021, 39, 2791-2802.	1.6	32
31	Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2021, 157, 147-155.	2.0	30
32	INSIGHT 2: a phase II study of tepotinib plus osimertinib in <i>MET</i>-amplified NSCLC and first-line osimertinib resistance. <i>Future Oncology</i> , 2022, 18, 1039-1054.	2.4	30
33	Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Nonâ€™™Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations. <i>Cancer Discovery</i> , 2022, 12, 1676-1689.	9.4	30
34	Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, e124-e127.	1.1	28
35	Will the clinical development of 4th-generation â€™™double mutant activeâ€™™ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?. <i>Translational Oncology</i> , 2021, 14, 101191.	3.7	24
36	<p>Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification</p>. <i>Lung Cancer: Targets and Therapy</i> , 2019, Volume 10, 21-26.	2.7	22

#	ARTICLE	IF	CITATIONS
37	Catalog of 5â€² fusion partners in RET+ NSCLC Circa 2020. JTO Clinical and Research Reports, 2020, 1, 100037.	1.1	17
38	Identification of a novel T1151K ALK mutation in a patient with ALK -rearranged NSCLC with prior exposure to crizotinib and ceritinib. Lung Cancer, 2017, 110, 32-34.	2.0	16
39	Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RETâ€²-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib. Journal of Thoracic Oncology, 2021, 16, e51-e54.	1.1	16
40	How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC). Translational Lung Cancer Research, 2020, 9, 2521-2534.	2.8	15
41	The Panâ€²Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. Oncologist, 2020, 25, e39-e47.	3.7	13
42	A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review. JTO Clinical and Research Reports, 2021, 2, 100116.	1.1	12
43	Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. JTO Clinical and Research Reports, 2021, 2, 100187.	1.1	11
44	Safety of alectinib for the treatment of metastatic<i>ALK</i>-rearranged non-small cell lung cancer. Expert Opinion on Drug Safety, 2017, 16, 509-514.	2.4	10
45	A rare case of choroid plexus carcinoma that led to the diagnosis of Lynch syndrome (hereditary) Tj ETQq1 1 0.784314 rgBT /Overlock	1.4	9
46	Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK-Positive Nonâ€²Small-Cell Lung Cancer: Histologic Analysis. Clinical Lung Cancer, 2019, 20, e77-e80.	2.6	9
47	Identification of Novel CDH1-NRG2Î± and F11R-NRG2Î± Fusions in NSCLC Plus Additional Novel NRG2Î± Fusions in Other Solid Tumors by Whole Transcriptome Sequencing. JTO Clinical and Research Reports, 2021, 2, 100132.	1.1	7
48	Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation. Lung Cancer: Targets and Therapy, 2018, Volume 9, 111-116.	2.7	6
49	<p>Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases</p>. Lung Cancer: Targets and Therapy, 2020, Volume 11, 13-18.	2.7	6
50	Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations. Lung Cancer: Targets and Therapy, 2021, Volume 12, 61-65.	2.7	6
51	The Next Target for NSCLC: Let It Be â€²RETâ€². Journal of Thoracic Oncology, 2020, 15, 1803-1805.	1.1	1
52	Multimodal Bronchoscopic Treatment of Unresectable Tracheal Adenoid Cystic Carcinoma. Journal of Bronchology and Interventional Pulmonology, 2020, 27, e17-e19.	1.4	1
53	Pacific Rim redux: lorlatinib, the ultimate Jaeger?. Annals of Translational Medicine, 2018, 6, S40-S40.	1.7	1
54	ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer. Translational Lung Cancer Research, 2016, 5, 660-664.	2.8	0

#	ARTICLE	IF	CITATIONS
55	MET ex14-Positive NSCLC: Time to Take the Therapy to the Target to Aim for a Cure?. Journal of Thoracic Oncology, 2017, 12, 1180-1182.	1.1	0
56	Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-Î± N848â€‰%K mutation. Lung Cancer, 2018, 124, 86-89.	2.0	0
57	Ensartinib (X-396), an Approved ALK Inhibitor, Falls Out as a Clinically Relevant ROS1 Inhibitor. Journal of Thoracic Oncology, 2021, 16, 1778-1781.	1.1	0